Forty Years of Research and Treatment in Immunology and Allergy: In Honor of Professor Reza Farid Hosseini
In light of various supports of prodigious figures in the field of immunology and allergy, the subject area has been faced a great leap during the last century. The current state of the discipline owes an abundant appreciation for the scholars motivated in escalating the true nature of the science, who left no stone unturned in improving the general common sense and understanding of the human knowledge in general, and immunology and allergy in particular. Professor Reza Farid Hosseini is among the dignitaries who invested his life and energy on weaving the tapestry of the immunology and allergy. He delivered a great deal of influence on the field by his ethical devotion to science and was a significant contributor in the realms of the human immune system. His presence drastically rehabilitated the place of the Immunology in Iran, and the current paper seeks to review the personal and academic life of Professor Reza Farid Hosseini in honor and appreciation for his in-depth involvement in the field. The paper summarizes Professor Farid’s childhood, school, and higher education, compilations, and translation of books, his contribution to the research both inside and outside of Iran, and scientific activities of Dr. Farid Hosseini.
2. Black CA. A brief history of the discovery of the immunoglobulins and the origin of the modern immunoglobulin nomenclature. Immunol Cell Biol. 1997;75(1):65-8.
3. Jafari R, Ranjbar A-R, Farid Hosseini R. A Biographical History of Some Iranian Pioneers in Medical Immunology and Allergy. Arch Iran Med. 2019;22(6):344-52.
4. Kchour G, Tarhini M, Kooshyar M-M, El Hajj H, Wattel E, Mahmoudi M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009;113(26):6528-32.
5. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011;52(3):172-6.
6. Abbaszadegan MR, Gholamin M, Tabatabaee A, Farid R, Houshmand M, Abbaszadegan M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol. 2003;41(6):2593-5.
7. Safai B, Huang JL, Boeri E, Farid R, Raafat J, Schutzer P, et al. Prevalence of HTLV type I infection in Iran: a serological and genetic study. AIDS Res Hum Retroviruses. 1996;12(12):1185-90.
8. Sabouri AH, Saito M, Usuku K, Bajestan SN, Mahmoudi M, Forughipour M, et al. Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J Gen Virol. 2005;86(Pt 3):773-81.
9. Vidal AU, Gessain A, Yoshida M, Tekaia F, Garin B, Guillemain B, et al. Phylogenetic classification of human T cell leukaemia/lymphoma virus type I genotypes in five major molecular and geographical subtypes. J Gen Virol. 1994;75 ( Pt 12):3655-66.
10. Rafatpanah H, Farid R, Golanbar G, Jabbari Azad F. HTLV-I Infection: virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals. Iran J Allergy Asthma Immunol. 2006;5(4):153-66.
11. Gallo RC. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene. 2005;24(39):5926-30.
12. Okayama A. Natural history of human T-lymphotropic virus type 1 (HTLV-1) infection. Rinsho Byori. 2005;53(9):837-44.
13. Tagaya Y, Matsuoka M, Gallo R. 40 years of the human T-cell leukemia virus: past, present, and future. F1000. Research. 2019;8.
14. Coffin JM. The discovery of HTLV-1, the first pathogenic human retrovirus. Proc Natl Acad Sci U S A. 2015;112(51):15525-9.
15. Shoeibi A, Etemadi M, Moghaddam Ahmadi A, Amini M, Boostani R. "HTLV-I Infection" Twenty-Year Research in Neurology Department of Mashhad University of Medical Sciences. Iranian journal of basic medical sciences. 2013;16(3):202-7.
16. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SAR, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses. 2012;28(9):1095-101.
17. Kchour G, Rezaee R, Farid R, Ghantous A, Rafatpanah H, Tarhini M, et al. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma. Retrovirology. 2013;10:91-.
18. Durham SR, Nelson H. Allergen immunotherapy: a centenary celebration. World Allergy Organ J. 2011;4(6):104-6.
19. Farid R, Ghasemi R, Baradaran-Rahimi M, Jabbari F, Ghaffari J, Rafatpanah H. Evaluation of six years allergen immunotherapy in allergic rhinitis and allergic asthma. Iran J Allergy Asthma Immunol. 2006;5(1):29-31.
20. Bidad K, Nicknam MH, Farid R. A review of allergy and allergen specific immunotherapy. Iran J Allergy Asthma Immunol. 2011;10(1):1-9.
21. Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in iran. Iran J Pediatr. 2010;20(1):16-34.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.